Postpartum Depression Treatment Market Size & Share 2026-2035

Postpartum Depression Treatment Market Size

The postpartum depression (PPD) treatment market was valued at USD 1.05 billion in 2025. The market is expected to grow from USD 1.14 billion in 2026 to USD 2.55 billion in 2035, growing at a CAGR of 9.4% during the forecast period, according to the latest report published by Global Market Insights Inc.

Another major factor is awareness and education about maternal mental health. Due to awareness campaigns and the inclusion of PPD screening as a routine part of postnatal care, the condition has become more widely recognized, reducing stigma and enabling more women to seek treatment for the condition. These factors position the postpartum depression treatment industry for robust growth, offering opportunities for innovation and development.

The postpartum depression treatment market has shown immense growth over the period 2022-2024, with the market expanding from USD 845.1 million in 2022 to USD 975.3 million in 2024. This expansion was largely driven by the rising focus on maternal mental health and a deeper understanding of the effects of postpartum depression on mothers and families. The rising accessibility of effective treatments, along with the expansion of telehealth services and digital mental health apps, has improved treatment accessibility globally. In addition, favorable government policies in maternal healthcare, along with rising investments in the development of new treatments, led to a rise in the adoption of effective treatments, thus fueling the growth of the market during this period.

Postpartum depression is a mood disorder that causes difficulty bonding with the infant, and it is characterized by feelings of sadness, anxiety, irritability, fatigue, difficulty in bonding with the child, and feelings of hopelessness and inadequacy. It affects the ability of the mother to care for her child, as well as the health of the mother and the child if it is not treated appropriately. Treatment for postpartum depression focuses on meeting the emotional, hormonal, and physical health needs of mothers to overcome the illness. Treatment includes pharmacotherapy, such as antidepressant drugs and hormone therapy. Key players such as Supernus Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline, Novartis, and others are leading the market and driving market growth through the introduction of innovative therapies and expanding their global reach.

Postpartum Depression Treatment Market Trends

• Increasing prevalence of postpartum depression is a key trend driving the growth of the postpartum depression treatment industry. Modern lifestyles, stress, and hormonal imbalances contribute to the increasing number of PPD cases globally. For instance, as per postpartum depression statistics by the Postpartum Depression Organization, around 1 in 10 women experience postpartum depression after childbirth, although some studies suggest the prevalence may be as high as 1 in 7.
• This growing prevalence underscores the critical need for effective postpartum depression treatments, driving innovation, awareness campaigns, and investments in the PPD treatment market to support the well-being of mothers and their families.
• With greater awareness of the condition, more women are being diagnosed and seeking treatment, propelling market demand.
• In addition to this, healthcare providers are increasingly implementing routine postpartum screening programs, enabling early detection and intervention, which contributes to greater demand for effective treatments.
• Additionally, the availability of innovative therapies like brexanolone has revolutionized care for severe PPD, offering rapid relief compared to traditional antidepressants.
• Further, the ongoing investments by pharmaceutical companies in research and development of rapid-acting and novel antidepressants are fostering innovation and reinforcing the expansion of the postpartum depression treatment market globally.
• Moreover, the adoption of telehealth and digital mental health platforms has improved access to postpartum depression care, particularly for women in remote or underserved regions, facilitating timely consultations and follow-up care.
• These trends have resulted in higher treatment-seeking behavior and increased adoption of therapies, fueling market expansion and encouraging innovation in treatment options.

Postpartum Depression Treatment Market Analysis

Based on the type, the global market is segmented into postpartum anxiety, postpartum blues, postpartum post-traumatic stress disorder (PTSD), postpartum obsessive-compulsive disorder (OCD), postpartum panic disorder, and postpartum psychosis. The postpartum anxiety segment dominated the market with 23.4% of market share in 2025.

• Postpartum anxiety is an important problem worldwide, and it affects a considerable number of women. For instance, according to the National Institutes of Health, while anxiety levels may decrease after childbirth, one in five women remains highly anxious during the postpartum period, underscoring the condition’s prevalence and need for effective management.
• In addition, the focus on maternal mental health, as well as initiatives to increase access to treatment and eliminate cultural stigma, has helped increase the rate of diagnosis and treatment.
• Further, telemedicine and digital solutions have played a significant role in reaching underserved areas, offering convenient and accessible care options, thereby driving the growth of the postpartum anxiety segment in the market.
• On the other hand, the postpartum post-traumatic stress disorder (PTSD) segment is expected to grow at 9.9% CAGR over the analysis period.
• This growth can be attributed to increasing recognition of postpartum PTSD as a distinct condition that significantly affects maternal mental health and family well-being.
• In addition, the development of specialized therapies, including trauma-focused psychotherapy, pharmacological interventions, and digital mental health platforms, is enhancing treatment accessibility and effectiveness and is thereby expected to drive the growth of this segment.

Based on the treatment, the global postpartum depression treatment market is categorized into pharmacotherapy, hormone therapy, and other treatments. The pharmacotherapy segment is further sub-categorized into selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCA), and other pharmacotherapies. The pharmacotherapy segment was valued at USD 591 million in 2025 and has the potential to grow at a CAGR of 9.3%.

• The growth of this segment can be attributed to a combination of increasing demand, innovative treatments, and improved accessibility to treatment.
• One of the major factors that has led to the growth of this segment is the efficacy of pharmacotherapy in the management of PPD symptoms. Pharmacotherapy, such as SSRIs and SNRIs, is widely used due to its safety and efficacy, especially in managing both depression and anxiety at the same time.
• Furthermore, the high incidence rate of anxiety among women experiencing PPD has led to an increase in the demand for dual-action medications such as SSRIs and SNRIs, which are effective in managing both depression and anxiety.

Based on the route of administration, the global postpartum depression treatment market is divided into oral, parenteral, and other routes of administration. The oral segment accounted for the highest market share and is expected to reach USD 1.7 billion by the end of the analysis period.

• This dominance is primarily driven by the convenience and ease of administration that oral medications offer. For new mothers managing childcare and recovery, oral treatments provide a practical solution, allowing them to adhere to prescribed therapies without requiring clinical supervision or invasive procedures.
• Additionally, the wide availability of oral antidepressants contributes to this segment's growth.
• Moreover, the suitability of oral medications for long-term use aligns well with the nature of PPD, which often requires sustained treatment for optimal recovery.
• With these advantages, the oral segment is anticipated to witness high growth over the forecast period.
• On the other hand, the parenteral segment is anticipated to grow at 9.7% CAGR over the forecast period.
• This growth is driven by the increasing use of injectable therapies for severe postpartum depression cases, such as neurosteroid-based treatments, which offer a rapid onset of action compared to oral antidepressants.
• Parenteral administration ensures higher bioavailability and faster therapeutic effects, making it a preferred option in hospital and clinical settings for acute PPD management, and is expected to grow in the coming years.

Based on the distribution channel, the global postpartum depression treatment market is classified into hospital pharmacies, retail pharmacies, and online pharmacies. In 2025, the hospital pharmacies segment held 47.3% market share.

• Hospital pharmacies are the primary distribution centers for advanced drugs like brexanolone (Zulresso), which is the first drug to be FDA-approved for the treatment of postpartum depression. This advanced drug has to be administered intravenously, thus making hospital pharmacies a major factor in the industry.
• The integration of hospital pharmacies with inpatient and outpatient services also plays a role in their dominance in the market.
• Additionally, the expertise of healthcare professionals in hospital pharmacies also ensures the safe use of drugs, thus contributing to the rise of hospital pharmacies.

North America Postpartum Depression Treatment Market

The North America market was valued at USD 434.6 million in 2025.

• The growth of this region is driven by the high prevalence of postpartum depression and the strong awareness of maternal mental health across the region. Advanced healthcare infrastructure, widespread screening programs, and improved access to mental health professionals have enabled early diagnosis and treatment among new mothers.
• The presence of major pharmaceutical companies such as Eli Lilly and Company, Pfizer, GlaxoSmithKline, and Novartis has strengthened the market through continuous research, development, and commercialization of innovative therapies.

The U.S. postpartum depression treatment market in 2025 was valued at USD 398.8 million and is anticipated to grow at 9.1% CAGR over the coming years.

• This growth is driven by several factors, including the increasing prevalence of postpartum depression among women, greater awareness of maternal mental health, and the availability of advanced treatment options.
• Additionally, the U.S. healthcare system's strong infrastructure, coupled with supportive policies and insurance coverage for mental health conditions, has significantly contributed to the accessibility and adoption of PPD treatments.

Europe Postpartum Depression Treatment Market

Europe postpartum depression treatment market was valued at USD 292.6 million in 2025.

• The growth is driven by the rising focus on maternal mental health and increasing recognition of postpartum depression across the region. Growing awareness among healthcare professionals and new mothers has led to higher screening and diagnosis rates, supporting demand for effective treatments.
• Additionally, strong healthcare systems and access to specialized psychiatric and maternal care services across European countries have improved treatment availability.
• Furthermore, supportive government initiatives, increased research activities in maternal mental health, and expanding access to counselling and digital mental health services are further strengthening the postpartum depression treatment market in Europe.

Germany postpartum depression treatment market is expected to experience significant growth.

• The rise of telemedicine platforms in Germany is making mental health services more accessible, especially in rural or underserved areas, contributing to increased treatment uptake.
• Further, the country’s strong pharmaceutical and biotechnology industries are investing in research and development of new therapies for PPD. This focus on innovation is expected to bring more effective treatment options to the market in the near future.

Asia Pacific Postpartum Depression Treatment Market

Asia Pacific postpartum depression treatment market is expected to grow at 9.8% CAGR over the analysis period, primarily driven by the region’s large and growing birth population, which increases the number of women at risk of postpartum mental health conditions.

• Rapid urbanization, changing family structures, and increasing work-life stress among new mothers are contributing to a higher incidence of postpartum mental health challenges, thereby increasing demand for treatment.
• Additionally, the expansion of maternal healthcare programs, improved access to obstetric and psychiatric care in urban centers, and the growing presence of private healthcare providers are supporting market growth.

India postpartum depression treatment market is anticipated to witness high growth during the forecast period.

• According to an article published by the National Institutes of Health, PPD occurs in around 22% of new mothers in India, highlighting the significant need for effective treatments.
• This high prevalence is attributed to various factors, including social and cultural pressures, lack of support systems, and hormonal changes post-childbirth. The growing recognition of this widespread issue is driving the demand for targeted therapies to manage PPD effectively.
• Additionally, as nuclear families and dual-income households become more common in India, the lack of traditional support systems for new mothers is contributing to increased recognition of postpartum mental health challenges. This societal shift is amplifying the need for formalized PPD treatment options.

Latin America Postpartum Depression Treatment Market

Brazil's market is expected to experience significant growth over the analysis period.

• The market is set to grow due to increasing awareness of maternal mental health, high prevalence rates, and improving healthcare infrastructure.
• Further, the country’s expanding healthcare system, coupled with affordable antidepressant therapies provided by local pharmaceutical companies, is making treatment more accessible.
• Moreover, partnerships between healthcare organizations and non-profits are fostering education and outreach efforts, strengthening market growth.

Middle East and Africa Postpartum Depression Treatment Market

Saudi Arabia market is poised to grow in the coming years.

• The market is poised for growth, supported by rising awareness of maternal mental health, changing cultural attitudes, and improved healthcare accessibility.
• Cultural shifts are reducing stigma around mental health, encouraging more women to seek treatment.
• Additionally, the introduction of advanced therapies, combined with supportive government policies emphasizing maternal and child health, is driving early diagnosis and adoption of PPD treatments across the country.

Postpartum Depression Treatment Market Share

The postpartum depression treatment industry is characterized by a competitive landscape with several key players striving to capture market share through innovative therapies and strategic collaborations. Key players such as Supernus Pharmaceuticals, Eli Lilly and Company, GlaxoSmithKline, Novartis, and Pfizer accounted for 56.8% of the market share and are leading the market with a strong focus on research and development, introducing advanced pharmacological solutions. Strategic alliances, mergers, and acquisitions are common as companies aim to expand their geographic reach and enhance product portfolios.

In addition, the market is witnessing increased investments in the development of novel neurosteroid therapies and fast-acting antidepressants designed specifically for postpartum depression. Companies are prioritizing clinical trials and regulatory approvals to bring innovative treatment options to market, while also focusing on improving drug efficacy and safety profiles. The growing emphasis on precision medicine and hormone-based treatments is further encouraging pharmaceutical firms to develop targeted therapies that address the unique biological mechanisms associated with postpartum depression.

Postpartum Depression Treatment Market Companies

Prominent players operating in the postpartum depression treatment industry include:

• AstraZeneca
• Bausch Health Companies
• Cipla
• Eli Lilly and Company
• GlaxoSmithKline
• Merck
• Novartis
• Pfizer
• Sun Pharmaceutical Industries
• Supernus Pharmaceuticals
• Takeda Pharmaceutical
• Teva Pharmaceutical Industries

• Supernus Pharmaceuticals

Following the acquisition of Sage Therapeutics, Supernus Pharmaceuticals has emerged as a leading player in the PPD treatment market, accounting for approximately 14.7% of the market. The company’s strong competitive position is driven by innovative neurosteroid-based therapies specifically developed for postpartum depression. Supported by strategic collaborations, robust clinical research, and a focus on rapid-acting, effective treatments, Supernus is well-positioned to expand adoption and strengthen its global market presence.

• Pfizer

Pfizer holds a considerable share in the market, driven by its diversified CNS drug portfolio and extensive global presence. The company strengthens its competitive edge through research investments, strategic collaborations, and a wide distribution network, improving accessibility and adoption of antidepressant therapies for postpartum depression.

Postpartum Depression Treatment Industry News

• In September 2025, Biogen received European Commission approval for ZURZUVAE (zuranolone), marking it as the first and only treatment for postpartum depression approved for women in Europe. This approval enabled Biogen to expand its market presence in the European PPD segment and capture early-mover advantages in a largely untapped region.
• In July 2025, Supernus Pharmaceuticals announced the successful completion of its previously disclosed acquisition of Sage Therapeutics. The acquisition strengthened Supernus’ presence in neuropsychiatric conditions by adding the innovative commercial product ZURZUVAE (zuranolone) along with a novel CNS discovery platform, accelerating mid- to long-term revenue and cash flow growth while further diversifying its revenue base.
• In August 2023, Sage Therapeutics, Inc. and Biogen Inc. announced that the U.S. Food and Drug Administration had approved ZURZUVAE (zuranolone) 50 mg for the treatment of adults with postpartum depression (PPD). This helped the companies to strengthen their product portfolio and generate revenue.

The postpartum depression treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2035 for the following segments:

Click here to Buy Section of this Report

Market, By Type

• Postpartum anxiety
• Postpartum blues
• Postpartum post-traumatic stress disorder (PTSD)
• Postpartum obsessive-compulsive disorder (OCD)
• Postpartum panic disorder
• Postpartum psychosis

Market, By Treatment

• Pharmacotherapy
  • Selective serotonin reuptake inhibitors (SSRIs)
  • Serotonin norepinephrine reuptake inhibitors (SNRIs)
  • Tricyclic antidepressants (TCA)
  • Other pharmacotherapies
• Hormone therapy
• Other treatments

Market, By Route of Administration

• Oral
• Parenteral
• Other routes of administration

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE